Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home | Companies

Medivation Inc

Medivation Inc
36th Floor
525 Market Street
San Francisco
United States of America
Phone: 1 415 5433470
Fax: 14-15-5433411
www.medivation.com

Company Overview

Top Competitors


Key Employees

David T. Hung, M.D.

President, Director, Chief Executive Officer, Executive Board

Kim D. Blickenstaff

Chairman, Executive Board

Wendy L. Yarno

Director, Non Executive Board

Dawn Svoronos

Director, Non Executive Board

Kathryn E. Falberg

Director, Non Executive Board

Michael L. King

Director, Non Executive Board

C. Patrick Machado

Director, Non Executive Board

W. Anthony Vernon

Director, Non Executive Board

Jennifer Jarrett

Chief Financial Officer, Senior Management

Joseph Lobacki

Chief - Commercial Officer, Senior Management

Mohammad Hirmand

Interim Chief Medical Officer, Senior Management

Sandy Cooper

Senior Vice President - Human Resources, Senior Management

Marion McCourt

Chief Operating Officer, Senior Management

Andrew Powell

General Counsel, Secretary, Senior Management

Locations/Subsidiaries


36th Floor,
525 Market Street,
San Francisco,
California,
United States of America
Phone: 1 415 5433470
Fax: 1 415 5433411

Medivation Europe Ltd

c/o Buzzacott LLP,
130 wood Street,
London,
England,
United Kingdom

Medivation Field Solutions Inc

Delaware,
United States of America

Medivation Neurology, Inc.

201 Spear St # 3,
San Francisco,
California,
United States of America
Phone: 1 415 5433470

Medivation Prostate Therapeutics Inc

Suite 400,
2711 Centerville Rd,
Wilmington,
Delaware,
United States of America

Medivation Services Inc

Delaware,
United States of America

Medivation Technologies, Inc.

Delaware,
United States of America

Products/Services


Products:

  • Products
  • XTANDI (metastatic castration resistant prostate cancer)
  • Pipeline:
  • Enzalutamide (non-metastatic CRPC)
  • Enzalutamide (non-metastatic HSPC)
  • Enzalutamide (metastatic HSPC)
  • Enzalutamide (hepatocellular carcinoma)
  • Enzalutamide (AR+ TNBC)
  • Enzalutamide (ER/PR+ & HER2 normal breast cancer)
  • Enzalutamide (AR+ HER2 amplified breast cancer)
  • Talazoparib (MDV3800) (gBRCA mutated advanced HER2 normal breast cancer)
  • Pidilizumab (MDV9300) (Relapsed or refractory diffuse large B-cell lymphoma)
  • MDV4463 (Nonalcoholic steatohepatitis)